Semaglutide, an Anti-Diabetic and Anti-Obesity Drug: A Perspective

Abstract

Glucagon-Like Peptide-1 (GLP-1) receptor agonist often used in treatment of type 2 diabetes mellitus and obesity: Semaglutide It improves glycemic control by increasing insulin secretion, inhibiting glucagon release, slowing stomach emptying and lowering appetite. Due to its lengthy half-life, semaglutide can be given once weekly, leading to better patient compliance than daily therapy. Clinical trials have shown considerable declines in glycated hemoglobin (HbA1c), body weight, and cardiovascular risk in people receiving semaglutide. Semaglutide has demonstrated significant effectiveness in achieving durable weight loss in conjunction with lifestyle changes for the management of obesity. Emerging data also suggest possible benefits in lowering inflammation, enhancing metabolic health, and preventing cardiovascular problems. This drug has therapeutic benefits but commonly causes nausea, vomiting, diarrhea and gastrointestinal upset, particularly when the dose is being increased. Rare but serious issues, like pancreatitis and thyroid-related consequences, require close monitoring. Overall, semaglutide represents an important step forward in the management of metabolic disorder, providing good glycemic control, significant weight loss, and an attractive clinical profile.